SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con

FG-3246 and enzalutamide combination therapy, in biomarker unselected patients with androgen receptor pathway inhibitor (ARPI)-treated, taxane-naïve metastatic castration-resistant prostate cancer (mCRPC), led to a median radiographic progression free survival (rPFS) of 7.0 months in the overall study cohort, with median rPFS of 10.1 months observed in patients who progressed on only one prior ARPIHigher tumor uptake of FG-3180, a CD46 directed PET imaging agent, demonstrated a trend towards higher probability of PSA50 response, highlighting its potential for patient selection Combination therapy had a similar safety and exposure profile to the previous FG-3246 Phase 1 monotherapy trialResul

SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), today announced that the company's management will participate in the following investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation Date & Time: Thursday, February 26, 2026, 2:40-3:10 PM ET Location: Virtual Webcast: https://event.summitcast.com/view/ Leerink Global Healthcare ConferenceFormat: Corporate Presentation Date & Time: Wednesday, March 11, 2026, 2:20-2:50 PM ETLocation: Miami, FL Webcast: https://event.summitcast.com/view/ Kyntra Bio's management team will be available for one-on-one meetings during the confere

4 - KYNTRA BIO, INC. (0000921299) (Issuer)

4 - KYNTRA BIO, INC. (0000921299) (Issuer)

4 - KYNTRA BIO, INC. (0000921299) (Issuer)

4 - KYNTRA BIO, INC. (0000921299) (Issuer)

SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (NASDAQ:KYNB), formerly FibroGen (NASDAQ:FGEN), will announce fourth quarter and full year 2025 financial results on Monday, March 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationKyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the con